Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

CertaraApril 28, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Blog Knowledge Base

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 16, 2026 When I first began learning about pharmacokinetics (PK), I was often…

CertaraApril 16, 2026

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

CertaraApril 10, 2026

Blog

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…

CertaraApril 9, 2026

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

CertaraApril 2, 2026

Publication

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

This study demonstrates how a model-informed, totality-of-evidence approach was used to select the optimal clinical…

Danielle PillsburyApril 2, 2026

Blog Knowledge Base

Where Did the 80-125% Bioequivalence Criteria Come From?

Discover what bioequivalence criteria mean, why the 80-125% bioequivalence range is used, and how custom…

CertaraMarch 27, 2026

Case Study

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

PK/PD Modeling for CNS drug development using Phoenix NLME and machine learning for better CNS…

CertaraMarch 26, 2026

Publication

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

This review article examines the development of radiopharmaceutical imaging agents and radioligand therapies for pediatric…

CertaraMarch 26, 2026

Modeling and Simulation – PK/PD

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Where Did the 80-125% Bioequivalence Criteria Come From?

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Newsletter sign up

Quick links

Solutions

Contact